Checking Up on GSK in China

When thinking through an FCPA risk assessment, one thing usually not considered adequately is a company’s sales culture. To see the consequences of that, one need look no further than GSK’s corruption troubles in China—but, CW blogger Tom Fox writes, the reforms GSK has implemented with its sales force are ...

THIS IS MEMBERS-ONLY CONTENT

SINGLE MEMBERSHIP                                             CORPORATE MEMBERSHIP

You are not logged in and do not have access to members-only content.

If you are already a registered user or a member, SIGN IN now.